MICAD adds 23 new molecular imaging, contrast agents

Molecular Imaging and Contrast Agent Database (MICAD) has added 23 molecular imaging and contrast agents, totaling 883 in the MICAD database.

The new PET agents are:
  • [18F]FEDAC;
  • [18F]FEAC which targets peripheral-type benzodiazepine receptor;
    • 64Cu-DOTA-C-ANF which targets natriuretic peptide clearance receptor;
    • [11C]JHU76609 which targets cannabinoid CB1 receptors;
    • [18F]RP1004 which targets mitochondrial complex 1;
    • [11C]RIF which targets DNA-dependent RNA polymerase in bacterial cells;
    • 64Cu-PEG12 AVP04-07 which targets tumor-associated glycoprotein 72;
    • 68Ga-CHX-A”-ReCCMSH (Arg11); and
    • 86Y-CHX-A”-ReCCMSH (Arg11), which targets melanocortin-1 receptor.
     
    The new SPECT agents are:
    • 99mTc-anti-RAGE pF (ab’) 2;
    • 99mTc-anti-RAGE mF (ab’) 2, which targets receptor for advanced glycation endproducts;
    • [125I]-ch806;
    • [111In]-CHX-A”-DTPA-ch806, which targets epidermal growth factor receptor deletion variant de2-7;
    • [111In]-ABY-025, which targets epidermal growth factor receptor 2;
    • [111In]-DOTA-cG250;
    • [111In]-DOTA-F (ab’) 2-cG250; and
    • [111In]-DOTA-Fab-cG250, which targets carbonic anhydrase IX.

    The new ultrasound agent is:
    • PFC-S60-PEG40S-NB, which is non targeting.

    The new MRI agents are:
    • P975; and
    • LIBS-MIPOs, which targets platelet glycoprotein GPIIb/IIIa receptor.
     
    The new optical agents are:
    • 5-carboxy-fluorescein-labeled octreotate, which targets somatostatin receptors;
    • Haff682, which targets epidermal growth factor HER2 receptor; and
    • Eaff800, which targets epidermal growth factor receptor, HER1.

      Around the web

      Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

      Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

      After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.